Losartan 0.08% Ophthalmic Solution

Losartan 0.08% Ophthalmic Solution is for topical ophthalmic use and is commonly used to treat corneal scarring fibrosis, and other eye diseases and disorders. Classed as an angiotensin II receptor blocker (ARB).

• Volume: 6mL or 12mL
• Strength: 0.08%
• We exclusively compound Losartan 0.08% Ophthalmic Solution for ophthalmic use only.
• It is compounded in a sterile compounding facility that is <795>, <797> and <800> chapter compliant.

References:

1. Sampaio LP, Hilgert GSL, Shiju TM, Santhiago MR, Wilson SE. Topical losartan and corticosteroid additively inhibit corneal stromal myofibroblast generation and fibrosis after alkali burn injury. Transl Vis Sci Technol. 2022;11(7):9. PMID: 35811366. https://pubmed.ncbi.nlm.nih.gov/35811366/
2. Quigley HA, Pitha IF, Welsbie DS, et al. Losartan treatment protects retinal ganglion cells and alters scleral remodeling in experimental glaucoma. PLoS One. 2015;10(10):e0141137. PMID: 26448393. https://pubmed.ncbi.nlm.nih.gov/26448393/
3. Wilson SE. Molecular cell biology for corneal wound healing and fibrosis. Ophthalmology. 2020;127(1):S17-S30. PMID: 31727402. https://pubmed.ncbi.nlm.nih.gov/31727402/
4. Saika S. TGF-β pathobiology in corneal wound healing. Cornea. 2004;23(8 Suppl):S25-S30. PMID: 15502472. https://pubmed.ncbi.nlm.nih.gov/15502472/

Learn More – Ophthalmic Compounding of Losartan